Janney Montgomery Scott LLC Has $15.41 Million Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Janney Montgomery Scott LLC decreased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 7.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,564 shares of the company's stock after selling 4,197 shares during the period. Janney Montgomery Scott LLC owned 0.17% of Medpace worth $15,406,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Medpace by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock worth $854,087,000 after buying an additional 25,704 shares in the last quarter. Invesco Ltd. lifted its position in Medpace by 91.8% during the 4th quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock worth $360,387,000 after buying an additional 519,186 shares in the last quarter. Wasatch Advisors LP lifted its position in Medpace by 3.1% during the 4th quarter. Wasatch Advisors LP now owns 936,842 shares of the company's stock worth $311,247,000 after buying an additional 28,161 shares in the last quarter. Geode Capital Management LLC lifted its position in Medpace by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock worth $218,031,000 after buying an additional 28,076 shares in the last quarter. Finally, Bessemer Group Inc. lifted its position in Medpace by 15.0% during the 4th quarter. Bessemer Group Inc. now owns 576,044 shares of the company's stock worth $191,379,000 after buying an additional 75,275 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $302.69 on Thursday. The company has a market capitalization of $8.70 billion, a price-to-earnings ratio of 23.11, a P/E/G ratio of 5.38 and a beta of 1.47. The firm's 50 day simple moving average is $299.23 and its 200 day simple moving average is $321.96. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.31% and a return on equity of 54.36%. During the same period last year, the company posted $3.20 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently issued reports on MEDP. Leerink Partners began coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target on the stock. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Truist Financial cut their target price on shares of Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research report on Wednesday, April 23rd. William Blair restated a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Finally, Robert W. Baird cut their target price on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Eleven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $349.30.

Insider Activity at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the sale, the director now directly owns 2,998 shares in the company, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 20.30% of the stock is currently owned by corporate insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.